A 2026 randomized, double-blind, placebo-controlled trial published in the Journal of Ginseng Research reveals that red ginseng reduces menopausal symptoms, including hot flashes and sleep disturbances, among women aged 45 to 60, without altering female hormone levels or endometrial thickness.
Red Ginseng Beverage Reduces Menopausal Symptoms and Cholesterol
- What was tested: Researchers evaluated whether daily intake of a red ginseng beverage over 90 days could alleviate typical menopausal discomforts compared to a placebo.
- The main finding: Women taking red ginseng experienced a greater reduction in total symptom scores—including hot flashes, sweating, irritability, depressive moods, and fatigue—alongside lower total and LDL cholesterol.
- The safety profile: The treatment did not induce significant changes in female hormone levels or the thickness of the uterine lining, indicating an action distinct from traditional hormone replacement therapy.
Clinical Trial Findings in the Journal of Ginseng Research
According to reporting published in collaboration with Premium Medical Circle, the 2026 study evaluated 112 participants between the ages of 45 and 60. Over a 90-day intervention period, participants ingested either a beverage containing red ginseng or an inactive placebo. Investigators deployed the Kupperman-Index to quantify symptom severity across multiple clinical domains.
After three months of daily administration, the cohort receiving red ginseng demonstrated a reduction in their cumulative symptom score relative to the placebo group. Documented improvements encompassed vasomotor symptoms such as hot flashes and hyperhidrosis, alongside neuropsychiatric parameters including irritability, depressive symptoms, and physical exhaustion. Metabolic assessments revealed a decline in serum total cholesterol and low-density lipoprotein (LDL) cholesterol levels among the ginseng recipients.
Previous Trials Show Ginseng Relieves Menopausal Symptoms
The 2026 findings align with earlier systematic evaluations. A 2022 systematic review and meta-analysis previously synthesized 15 placebo-controlled trials examining ginseng administration in peri- and postmenopausal women. That pooled analysis of three studies involving a cumulative total of 515 participants similarly documented superior relief of menopausal symptoms and hot flashes compared to placebo, alongside enhanced self-reported quality of life.
In the 2026 investigation, somatic sleep disruptions—frequently exacerbated by nocturnal vasomotor events—were explicitly tracked using the Athens Insomnia Scale. Participants consuming red ginseng reported superior sleep quality improvements compared to controls. Investigators continue to debate whether this restorative sleep benefit stems directly from neuroendocrine regulation or merely reflects the secondary relief of concurrent vasomotor triggers.
Hormonal Neutrality and Sexual Health Observations
Despite clinical improvements across multiple physiological markers, endocrine assays performed during the 2026 trial revealed no significant fluctuations in circulating female sex hormones. Measurements similarly confirmed that red ginseng administration did not alter the thickness of the endometrium, the mucosal lining of the uterus. This absence of estrogenic stimulation distinguishes the botanical extract from conventional hormone replacement therapies.
Secondary endpoints concerning female sexual function have also appeared in smaller historic trials. A double-blind, placebo-controlled study involving 32 women identified improvements in sexual arousal following red ginseng administration. A separate randomized trial of 62 postmenopausal women and an evaluation of 55 premenopausal women surgically induced into menopause due to gynecological malignancies reported similar trends favoring Panax ginseng or Korean red ginseng over placebo in specific sexual function domains.
| Study Parameter | Red Ginseng Intervention | Placebo Comparator |
|---|---|---|
| Sample Size (2026 Trial) | 112 participants total | 112 participants total |
| Duration | 90 days | 90 days |
| Primary Diagnostic Tool | Kupperman-Index | Kupperman-Index |
| Hormonal Impact | No significant estrogen/endometrial shift | No significant shift |
Patients Should Consult Physicians About Pharmacological Interactions
Patients must exercise caution regarding pharmacological interactions. Individuals managing chronic medical conditions or taking prescription pharmaceuticals should consult a physician or clinical pharmacist prior to initiating high-dose herbal regimens.
References
- Journal of Ginseng Research. (2026). Randomized, double-blind, placebo-controlled evaluation of red ginseng in menopausal women.
- Systematic Review and Meta-Analysis. (2022). Evaluation of ginseng efficacy in peri- and postmenopausal women.
- Athens Insomnia Scale. Clinical validation data for sleep disturbance assessment.
Worth a look
